Evaluation of cytokine pattern of diphtheria-tetanus vaccine in laboratory animal model

Subject Areas : Journal of Comparative Pathobiology

, A.  Fardipoor. ¹ (.Department of Pathobiology, Science and Research Branch, Islamic Azad University, Tehran, Iran.)
, T.  Zahraei Salehi ² (Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran.)
مجید  Tebyanian ³ (Department of Biotechnology, Razi Vaccine and Serum Research Institute, Agricultural Research Education and Extension Organization)
, R.  Yahyaraeyat ⁴ (Department of Microbiology and Immunology, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran)

Received: 2021-05-02 Accepted : 2021-05-02 Published : 2020-06-21

Keywords: Diphtheria-Tetanus vaccine, immunization, Immune response, Cytokine,

Abstract :

Due to universal vaccination program, the prevalence of many dangerous diseases among infants and adults has been significantly reduced. In order to obtain appropriate strategies for regulating immune responses that lead to increased vaccine efficacy, here we investigated the pattern of immune response following diphtheria-tetanus vaccine administration in mice model. Diphtheria (D) and tetanus (T) monovalent and divalent (DT) vaccines have been separately formulated in the presence and absence of adjuvant (aluminum phosphate gel). Each vaccine has been injected for 5 times in Balb/c mice.  Two weeks after the last injection, the spleen of the mice was removed and the spleen cells were exposed to the selected antigens and the levels of Interleukin 4 (IL-4) and IFN- ɤ (Interferon gamma) were measured in cell culture supernatant. According to our results, the levels of IL-4 was significantly increased in mice receiving adjuvant vaccines compared with the non-adjuvant and control groups, while this increase was not significant for IFN-Ƴ. This results mentioned that the orientation of immune responses is more towards T helper 2 responses (Th2), which could be related to the nature of the antigen, the vaccine formulation strategy and the percentage of antigen uptake in the alum gel.

References:

1-            WHO. Vaccine preventable deaths and the Global Immunization Vision and Strategy, 2006-2015. MMWR Morbidity and mortality weekly report. 2006;55(18):511.

2-            Nazari F, Mirchamsy H, Alé-Agha S, Mahinpour M. A model for developing countries of mass serological survey of children vaccinated against diphtheria and tetanus. J biol Stand. 1976;4:329-33.

3-            Di Pasquale A, Wolter J, Schuerman L. Management of pertussis in adolescents and adults: the role of a reduced-antigen content combined diphtheria-tetanus-acellular pertussis (dTpa) vaccine. Journal of preventive medicine and hygiene. 2005;46(1):33-41.

4-            Kitchin NR. Review of diphtheria, tetanus and pertussis vaccines in clinical development. Expert review of vaccines. 2011;10(5):605-15.

5-            Luo P, Qin L, Mao X, Chen L, Yu S, Li Q, et al. Identification of a novel linear epitope in tetanus toxin recognized by a protective monoclonal antibody: Implications for vaccine design. Vaccine. 2012;30(45):6449-55.

6-            Pellizzari R, Rossetto O, Schiavo G, Montecucco C. Tetanus and botulinum neurotoxins: mechanism of action and therapeutic uses. Philosophical Transactions of the Royal Society of London Series B: Biological Sciences. 1999;354(1381):259-68.

7-            Holmes RK. Biology and molecular epidemiology of diphtheria toxin and the tox gene. Journal of Infectious Diseases. 2000;181(Supplement_1):S156-S67.

8-            Embree J, Law B, Voloshen T, Tomovici A. Immunogenicity, safety, and antibody persistence at 3, 5, and 10 years postvaccination in adolescents randomized to booster immunization with a combined tetanus, diphtheria, 5-component acellular pertussis, and inactivated poliomyelitis vaccine administered with a hepatitis B virus vaccine concurrently or 1 month apart. Clin Vaccine Immunol. 2015;22(3):282-90.

9-            WHO. WHO Expert Committee on Biological Standardization, sixty-seventh report: World Health Organization; 2017.

10-          WHO. WHO Expert Committee on Biological Standardization: Sixty-Third Report: World Health Organization; 2014.

11-          WHO. Manual for quality control of diphtheria, tetanus and pertussis vaccines. World Health Organization; 2013.

12-          Yamamoto A, Nagata N, Ochiai M, Kataoka M, Toyoizumi H, Okada K, et al. Enhanced sensitisation of mice with diphtheria tetanus acellular pertussis vaccine to local swelling reaction to the booster immunisation. Vaccine. 2002;20(25-26):3088-94.

13-          Silva GP, Cruz SdC, Cruz AC, Milagres LG. Short-term and long-term antibody response by mice after immunization against Neisseria meningitidis B or diphtheria toxoid. Brazilian Journal of Medical and Biological Research. 2013;46(2):148-53.

14-          Gupta R, Griffin JP, Rivera R, Siber G. Development of an animal model to assess the immunogenicity of single-dose tetanus and diphtheria vaccines based on controlled release from biodegradable polymer microspheres. Developments in biological standardization. 1998;92:277-87.

15-          Ding Z, Van Riet E, Romeijn S, Kersten G, Jiskoot W, Bouwstra J. Immune modulation by adjuvants combined with diphtheria toxoid administered topically in BALB/c mice after microneedle array pretreatment. Pharmaceutical research. 2009; 26(7):1635-43.

16-          Rowe J, Macaubas C, Monger T, Holt BJ, Harvey J, Poolman JT,  Loh R, Sly PD, Holt PG.  Heterogeneity in Diphtheria-Tetanus–Acellular Pertussis Vaccine–Specific Cellular Immunity during Infancy: Relationship to Variations in the Kinetics of Postnatal Maturation of Systemic Th1 Function. The Journal of Infectious Diseases. 2001; 184: 80-88.

17-          Rowe J, Macaubas C, Monger TM, Holt BJ, Harvey J, Poolman JT, Sly PD, Holt PG. Antigen-specific responses to diphtheria-tetanus-acellular pertussis vaccine in human infants are initially Th2 polarized. 2000; 68: 3873-3877.

18-          Holt PG, Rudin A, Macaubas C, Holt BJ, Rowe J, Loh R, Sly PD. Development of immunologic memory against tetanus toxoid and pertactin antigens from the diphtheria-tetanus-pertussis vaccine in atopic versus nonatopic children. Journal of allergy and clinical immunology. 2000; 105: 1117-1122.

19-          Ibrahim EH, Kilany M, Mostafa OM, Shaker KH, Alshehri M, Alsyaad KM, et al. TH1/TH2 chemokines/cytokines profile in rats treated with tetanus toxoid and Euphorbia tirucalli. Saudi journal of biological sciences. 2019;26(7):1716-23.

20-          Cooper P, Espinel I, Paredes W, Guderian R, Nutman T. Impaired tetanus-specific cellular and humoral responses following tetanus vaccination in human onchocerciasis: a possible role for interleukin-10. The Journal of infectious diseases. 1998;178(4):1133-8.